Compare Abeona Therapeutics Inc (ABEO) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dicks Sporting Goods Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Dicks Sporting Goods Inc trades at $202.82 (market cap $18.35B). The key difference: Dicks Sporting Goods Inc is far larger — about 43.6× Abeona Therapeutics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DKS | |
|---|---|---|
Market Cap | $421.19M | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $239.17 |
52-Week Low | $4.17 | $187.78 |
Enterprise Value | $276.10M | $25.14B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
DKS trades at $203.44, down 4.98% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with strong profitability metrics including a 20.9% ROE and 4.71% net income margin. Analyst consensus is strongly bullish with a $263.22 price target and no sell ratings. Recent news highlights include positive coverage from Zacks and an upcoming Q2 2026 earnings call on August 25th.
The outlook remains positive given strong fundamentals and analyst support, but risks include competitive pressures and the stock's current bearish technical trend. The key near-term catalyst is the Q2 earnings report, which could validate the bullish sentiment if results meet or exceed the expected EPS of $3.77.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
